Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis - PubMed (original) (raw)
Comparative Study
doi: 10.1001/archpsyc.62.1.19.
Enrico Cagliero, Paul M Copeland, Christina P Borba, Anne Eden Evins, Doug Hayden, Mary T Weber, Ellen J Anderson, David B Allison, Tara B Daley, David Schoenfeld, Donald C Goff
Affiliations
- PMID: 15630069
- DOI: 10.1001/archpsyc.62.1.19
Comparative Study
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis
David C Henderson et al. Arch Gen Psychiatry. 2005 Jan.
Erratum in
- Incomplete Author Name in Byline.
[No authors listed] [No authors listed] JAMA Psychiatry. 2017 Jul 1;74(7):764. doi: 10.1001/jamapsychiatry.2017.1587. JAMA Psychiatry. 2017. PMID: 28564675 No abstract available. - Incomplete Author Name Indexed.
[No authors listed] [No authors listed] JAMA Psychiatry. 2018 Aug 1;75(8):866. doi: 10.1001/jamapsychiatry.2018.1565. JAMA Psychiatry. 2018. PMID: 29874358 No abstract available.
Abstract
Background: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
Objective: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.
Design: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
Setting: Subjects were recruited from an urban community mental health clinic and were studied at a general clinical research center. Patients Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous glucose tolerance test. Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
Main outcome measures: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
Results: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine), 29.5 +/- 17.5 months (olanzapine), and 40.9 +/- 33.7 (risperidone). Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04). There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]). The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02). There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
Conclusions: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects. Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
Similar articles
- Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC. Henderson DC, et al. J Clin Psychiatry. 2006 May;67(5):789-97. doi: 10.4088/jcp.v67n0513. J Clin Psychiatry. 2006. PMID: 16841629 - Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N, Sato Y, Furukori H, Saito M, Nakagami T, Kaneko S. Yasui-Furukori N, et al. J Clin Psychiatry. 2009 Jan;70(1):95-100. doi: 10.4088/jcp.07m03829. J Clin Psychiatry. 2009. PMID: 19026267 - Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS. Wu RR, et al. Psychopharmacology (Berl). 2006 Jul;186(4):572-8. doi: 10.1007/s00213-006-0384-5. Epub 2006 Apr 7. Psychopharmacology (Berl). 2006. PMID: 16601995 Clinical Trial. - Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Asmal L, et al. Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Cochrane Database Syst Rev. 2013. PMID: 24249315 Review. - Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.
Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Newcomer JW, et al. Arch Gen Psychiatry. 2002 Apr;59(4):337-45. doi: 10.1001/archpsyc.59.4.337. Arch Gen Psychiatry. 2002. PMID: 11926934 Review.
Cited by
- In vivo techniques for assessment of insulin sensitivity and glucose metabolism.
Hahn MK, Giacca A, Pereira S. Hahn MK, et al. J Endocrinol. 2024 Jan 31;260(3):e230308. doi: 10.1530/JOE-23-0308. Print 2024 Mar 1. J Endocrinol. 2024. PMID: 38198372 Free PMC article. Review. - Exploring the role of ketone bodies in the diagnosis and treatment of psychiatric disorders.
Omori NE, Malys MK, Woo G, Mansor L. Omori NE, et al. Front Psychiatry. 2023 Apr 17;14:1142682. doi: 10.3389/fpsyt.2023.1142682. eCollection 2023. Front Psychiatry. 2023. PMID: 37139329 Free PMC article. Review. - National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era.
Gao YN, Olfson M. Gao YN, et al. Schizophr Res. 2022 Oct;248:320-328. doi: 10.1016/j.schres.2022.09.023. Epub 2022 Sep 22. Schizophr Res. 2022. PMID: 36155305 Free PMC article. - Schizophrenia: a disorder of broken brain bioenergetics.
Henkel ND, Wu X, O'Donovan SM, Devine EA, Jiron JM, Rowland LM, Sarnyai Z, Ramsey AJ, Wen Z, Hahn MK, McCullumsmith RE. Henkel ND, et al. Mol Psychiatry. 2022 May;27(5):2393-2404. doi: 10.1038/s41380-022-01494-x. Epub 2022 Mar 9. Mol Psychiatry. 2022. PMID: 35264726 Review. - Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders.
Vassilopoulou E, Efthymiou D, Papatriantafyllou E, Markopoulou M, Sakellariou EM, Popescu AC. Vassilopoulou E, et al. J Pers Med. 2021 Nov 12;11(11):1189. doi: 10.3390/jpm11111189. J Pers Med. 2021. PMID: 34834541 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical